All In Biotech

Drug Trial Radar · NCT04822883

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

A Single-arm, Single-blind, Multiple Dose Study to Evaluate Safety and the Effects of RL-007 on Electroencephalograms and Event-related Potentials in Subjects With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Apr 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Apr 26, 2021

Primary completion

Oct 28, 2021

Study completion Oct 28, 2021

Sponsor

Lead sponsor
Recognify Life SciencesIndustry
Sponsor type
Industry
First posted
Mar 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia

Conditions

  • Cognitive Impairment
  • Schizophrenia

Interventions

  • RL-007Drug

    Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

  • RL-007 Matching PlaceboDrug

    Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAE)Time frame: Study Day 8.
  2. Change in blood pressure (systolic and diastolic) from baselineTime frame: Study Day 4
  3. Change in heart rate from baselineTime frame: Study Day 4
  4. Change in respiratory rate from baselineTime frame: Study Day 4
  5. Change in temperature from baselineTime frame: Study Day 4
  6. Change in electrocardiogram (ECG) from baselineTime frame: Study Day 3
  7. Change in the Columbia Suicide Severity Rating Scale (C-SSRS) from baselineTime frame: Study Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research

    Long Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.